We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$588M
1-Year Est. Return
182.75%
This Fund
S&P 500
This Quarter
Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
(+64%)
Cap. Flow
+$155M
Cap. Flow
% of AUM
40.41%
Top 10 Holdings %
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$20.5M |
| 2 |
Eli Lilly
LLY
|
+$16.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$9.45M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$7.89M |
| 5 |
argenx
ARGX
|
+$7.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$9.05M |
| 2 |
AbbVie
ABBV
|
+$8.88M |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$6.68M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$5.6M |
| 5 |
AstraZeneca
AZN
|
+$3.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Alector
ALEC
$171M
| $562K | 0.15% |
456,546
+217,527
| +91% | +$354K |
|
|
VERV
77
CALL
DELISTED
Verve Therapeutics
VERV
| $534K | 0.14% |
+116,900
| New | +$783K |
|
78
CALL
Summit Therapeutics
SMMT
$10.7B
| $476K | 0.12% |
24,700
+4,700
| +24% | +$94.3K |
|
79
CALL
Nektar Therapeutics
NKTR
$2.45B
| $461K | 0.12% |
+45,213
| New | +$591K |
|
|
FLNA
80
CALL
Filana Therapeutics
FLNA
$48.8M
| $450K | 0.12% |
+300,000
| New | +$757K |
|
81
uniQure
QURE
$3.05B
| $387K | 0.1% |
+36,500
| New | +$512K |
|
82
CALL
Compass Therapeutics
CMPX
$351M
| $380K | 0.1% |
+200,000
| New | +$532K |
|
83
Olema Pharmaceuticals
OLMA
$997M
| $376K | 0.1% |
+100,000
| New | +$503K |
|
84
PUT
Biomea Fusion
BMEA
$88.9M
| $362K | 0.09% |
170,100
+98,700
| +138% | +$336K |
|
|
UBX
85
CALL
DELISTED
Unity Biotechnology
UBX
| $361K | 0.09% |
+346,900
| New | +$627K |
|
86
CALL
Immunic
IMUX
$192M
| $346K | 0.09% |
+31,780
| New | +$343K |
|
87
CALL
Relay Therapeutics
RLAY
$4.21B
| $344K | 0.09% |
131,400
+31,400
| +31% | +$123K |
|
88
Gossamer Bio
GOSS
$85.6M
| $297K | 0.08% |
269,589
+51,602
| +24% | +$59.7K |
|
89
CALL
Capricor Therapeutics
CAPR
$251M
| $288K | 0.08% |
30,300
-169,700
| -85% | -$2.36M |
|
90
ProQR Therapeutics
PRQR
$248M
| $276K | 0.07% |
207,694
+49,671
| +31% | +$106K |
|
|
UBX
91
PUT
DELISTED
Unity Biotechnology
UBX
| $224K | 0.06% |
+215,200
| New | +$389K |
|
92
Eledon Pharmaceuticals
ELDN
$269M
| $219K | 0.06% |
64,613
-11,181
| -15% | -$46K |
|
|
MREO
93
Mereo BioPharma
MREO
$51.6M
| $169K | 0.04% |
+492,215
| New | +$1.39M |
|
|
ATYR
94
CALL
aTyr Pharma
ATYR
$50.9M
| $165K | 0.04% |
+54,700
| New | +$199K |
|
|
TERN
95
DELISTED
Terns Pharmaceuticals
TERN
| $155K | 0.04% |
56,098
+5,728
| +11% | +$23.4K |
|
96
Sagimet Biosciences
SGMT
$484M
| $150K | 0.04% |
+46,019
| New | +$193K |
|
97
Candel Therapeutics
CADL
$755M
| $142K | 0.04% |
25,045
+5,045
| +25% | +$41.2K |
|
|
MREO
98
PUT
Mereo BioPharma
MREO
$51.6M
| $88.7K | 0.02% |
+39,400
| New | +$111K |
|
|
ATYR
99
PUT
aTyr Pharma
ATYR
$50.9M
| $35.6K | 0.01% |
+11,800
| New | +$43K |
|
|
FLNA
100
PUT
Filana Therapeutics
FLNA
$48.8M
| $14.8K | ﹤0.01% |
9,900
-361,400
| -97% | -$912K |
|
Similar funds
MC
PFG
FMI
EGWAG
PFG
GIM
FL
BA
Diadema Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.
- Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
- Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
- Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
- Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
- Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
- Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
- Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.
Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.